Clearstead Trust LLC Acquires Shares of 1,727 Intuitive Surgical, Inc. (NASDAQ:ISRG)

Clearstead Trust LLC acquired a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 1,727 shares of the medical equipment provider’s stock, valued at approximately $583,000.

Several other hedge funds also recently made changes to their positions in the company. Commonwealth Equity Services LLC boosted its holdings in Intuitive Surgical by 10.9% in the 3rd quarter. Commonwealth Equity Services LLC now owns 61,148 shares of the medical equipment provider’s stock valued at $17,873,000 after purchasing an additional 6,018 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its holdings in Intuitive Surgical by 15.1% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 27,295 shares of the medical equipment provider’s stock worth $7,978,000 after acquiring an additional 3,589 shares during the period. J.W. Cole Advisors Inc. raised its position in Intuitive Surgical by 8.3% in the third quarter. J.W. Cole Advisors Inc. now owns 2,040 shares of the medical equipment provider’s stock worth $596,000 after acquiring an additional 156 shares in the last quarter. Sage Mountain Advisors LLC lifted its holdings in Intuitive Surgical by 7.7% in the third quarter. Sage Mountain Advisors LLC now owns 1,253 shares of the medical equipment provider’s stock valued at $366,000 after acquiring an additional 90 shares during the period. Finally, BNC Wealth Management LLC boosted its position in shares of Intuitive Surgical by 3.6% during the 3rd quarter. BNC Wealth Management LLC now owns 8,693 shares of the medical equipment provider’s stock worth $2,541,000 after purchasing an additional 299 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Wall Street Analyst Weigh In

ISRG has been the subject of several recent analyst reports. Stifel Nicolaus raised their price objective on shares of Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a research note on Monday, April 8th. Wells Fargo & Company boosted their price target on Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a research note on Friday, January 19th. Piper Sandler raised their price objective on Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a research note on Friday, April 19th. BTIG Research boosted their target price on Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research report on Friday, April 19th. Finally, Raymond James raised their price target on Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a research report on Thursday, January 25th. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $396.17.

Intuitive Surgical Stock Up 1.0 %

Shares of ISRG traded up $3.71 on Friday, hitting $381.36. 1,028,858 shares of the stock traded hands, compared to its average volume of 1,492,254. The firm has a market capitalization of $135.27 billion, a P/E ratio of 68.84, a P/E/G ratio of 4.88 and a beta of 1.39. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $403.76. The stock’s 50 day moving average is $385.40 and its two-hundred day moving average is $349.30.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. The company had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The business’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.00 EPS. Research analysts forecast that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Insider Buying and Selling

In related news, SVP Mark Brosius sold 196 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total value of $78,400.00. Following the sale, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at $736,800. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, SVP Mark Brosius sold 196 shares of the company’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the sale, the senior vice president now directly owns 1,842 shares in the company, valued at approximately $736,800. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Alan J. Levy sold 2,000 shares of the stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the transaction, the director now directly owns 25,319 shares in the company, valued at $9,385,753.30. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 226,928 shares of company stock worth $87,833,828. 0.90% of the stock is owned by company insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.